Vitamin K is a group of enzyme cofactors that enable carboxylation of proteins containing gamma-carboxyglutamate (Gla) domains. Apart from the constituents of the coagulation cascade other proteins belong to this group, including the matrix Gla protein (MGP, present in the vasculature). Importantly, MGP carboxylation is affected by vitamin K insuffi ciency in the fi rst line, long before clotting processes become disturbed. The resulting larger fraction of uncarboxylated MGP (ucMGP) favorizes arterial calcifi cation.
Introduction
Vitamin K is a group of enzyme cofactors that enable carboxylation of proteins containing gamma-carboxyglutamate (Gla) domains. Apart from the constituents of the coagulation cascade other proteins belong to this group, including the matrix Gla protein (MGP, present in the vasculature). Importantly, MGP carboxylation is affected by vitamin K insuffi ciency in the fi rst line, long before clotting processes become disturbed. The resulting larger fraction of uncarboxylated MGP (ucMGP) favorizes arterial calcifi cation.
This link between vitamin K and the cardiovascular health has been confi rmed by a number of studies in humans and animal models. For instance, in 1001 participants the levels of ucMGP were shown to correlate with vascular stiffness measured by pulse wave velocity calculated on the basis of applanation tonometry and this effect sustained after adjustment for potential confounders [1] . On a populational level, the insuffi cient supply of vitamin K2 in the diet was recently predicted to be responsible for 6.9% of cardiovascular mortality before the age of 65 years -more than the male gender (6.1%) [2] .
However, the data on the relationship between vitamin K status and the blood pressure are scarce, and particularly so in persons without the burden of cardiovascular risk factors. We performed a pilot study, in which we hypothesized that vitamin K defi ciency is associated with a higher blood pressure in young, healthy people.
Material and Methods
Healthy subjects were recruited in the year 2014 in the city of Poznan, Poland, as a control group for a study concerning atherosclerosis in cystic fi brosis [3] . The inclusion criterion was no acute or chronic disease. Exclusion criteria were: hypercholesterolemia or hypertriglyceridemia and early coronary disease or vascular brain diseases in the family (< 65 years in women and < 55 years in men).
As a proxy of vitamin K status we employed the level of protein induced by vitamin K absence-II (PIVKA-II). PIVKA-II concentrations above 2 ng/mL were considered to indicate moderate vitamin K defi ciency; they were determined in serum using enzyme-linked immunosorbent assay (MyBioSource, San Diego, USA).
Non-high density lipoprotein (non-HDL) cholesterol concentration was chosen and calculated as the most relevant supplementary cardiovascular risk factor. Total cholesterol was assessed with the use of an enzymatic method with esterase, cholesterol oxidase, and Trinder reaction. HDL cholesterol concentrations were measured employing glycerophosphate oxidase and Trinder reaction (Advia 1800 Chemistry, Siemens Healthcare, Erlangen, Germany).
Blood pressure was measured using a validated, automated oscillometric monitor Omron M5-I (Omron, Kyoto, Japan) [4, 5] in the Department of Cardiology-Intensive Therapy of Poznan University of Medical Sciences, Poznan, Poland. An average of three measurements was obtained for systolic (SBP) and diastolic (DBP) pressures and subsequently the mean arterial pressure (MAP) was calculated.
Statistical analyses were performed using Statistica 12 (Statsoft Inc., Tulsa, USA). The Shapiro-Wilk test was used to check for the normality of distribution in subgroups. The F-test was used to verify that there were no statistically signifi cant differences in variances between the compared subgroups. The hypothesis that mean values of parameters in subgroups are equal was tested using the Student's t-test. Correlations were checked by computing both Pearson's r and Spearman's ρ. Forward stepwise multivariable regression models were built to compensate for confounding, which included the following parameters: age, sex, BMI, non-HDL cholesterol, and PIVKA-II concentration. In additional explorative analyses the Mann-Whitney U-test was applied.
The study respected the rules and values set forth in the Declaration of Helsinki and was approved by the bioethical committee at Poznan University of Medical Sciences (decision no. 250/10). All the volunteers provided written, informed consent for their participation in the research.
Results
Twenty-three subjects were recruited for the study, of whom 16 were female (70%). The mean age was 21.3 ± 1.6 years. The average mass, height and body mass index (BMI) were: 60.2 ± 9.2 kg, 171 ± 9 cm, 20.6 ± 2.4 kg/m 2 . The PIVKA concentration in the group was varied: mean 3.85 ± 3.58 ng/mL (minimum 0.22, maximum 10.13 ng/mL). The average pressures were: SBP 113 ± 9 mmHg, DBP 63 ± 8 mmHg, and MAP 79 ± 8 mmHg. Non-HDL cholesterol concentration was 104 ± 32 mg/dL. The comparison of the above parameters in vitamin K-defi cient and vitamin K-suffi cient healthy persons is presented in Table 1 . A lower average diastolic and mean blood pressure was found in vitamin K-defi cient subjects (Figure 1) .
PIVKA-II levels correlated with DBP only (Pearson's R = -0.41, p < 0.05; Spearman's ρ ns.; Figure 2 ). Of the three regression models built to predict blood pressure values, only the one explaining DBP was valid. PIVKA-II alone was found to independently associate with DBP (adjusted R 2 = 13.1%, model p < 0.05; PIVKA-II: β = -0.41; 95%CI -1.87-(-0.00098), t = -2.08, p < 0.05). We performed explorative analyses to characterize the fi ve vitamin K-defi cient participants in whom DBP < 55 mHg was found (Figure 2 ). The fi ve subjects (4 female, 1 male) did not differ from the rest of the group nor from the other vitamin K-defi cient persons in age, weight, height, BMI, or non-HDL cholesterol concentration (all p values > 0.40). 
Discussion
This pilot study reveals an unexpected association between vitamin K defi ciency and a lower DBP in healthy subjects. This goes against the common knowledge, which focuses on the role of MGP and arterial calcifi cation. However, some indirect support for our fi ndings is provided by the study of Streit et al., who analyzed data regarding 4412 patients with hypertension, of whom 569 received phenprocoumon, a vitamin K antagonist. Even after the adjustment for potential confounding, the patients on phenprocoumon had lower mean SBP (-8.4 mmHg) and DBP (-1.5 mmHg). The authors proposed that this could be explained by better compliance to antihypertensive pharmacotherapy -our study adds that there might indeed be a mechanistic explanation to their observation.
Other research regarding vitamin antagonists also yielded important information on the role of Gla carboxylation in cardiovascular health. The Stroke Prevention in Nonrheumatic Atrial Fibrillation (SPINAF) trial, which investigated the impact of warfarin and placebo in 284 patients with atrial fi brillation, did not fi nd any changes in DBP after a mean follow-up of 24 months. A cohort study by Lim et al. followed 116 diabetes patients, half of whom received warfarin, over a period of 36 months. No increases in SBP in the warfarin group were found [6] . Unfortunately, blood pressure data are missing from many other vitamin K antagonists trials [7] .
Treatment with warfarin was proposed as an animal model for isolated systolic hypertension [8] and vitamin K was shown to rescue warfarin-induced increase in SBP [9] . Furthermore, a striking warfarin-induced vascular calcifi cation was found in rats with adenine-induced chronic kidney disease. In this case the effect was also mitigated by vitamin K [10] . In humans, total arterial calcium associated with a high osteocalcin ratio, which reflects vitamin K insuffi ciency [11] . A randomized study in postmenopausal women (n = 244) showed that supplementation of vitamin K2 (180 μg of menaquinone 7 -MK7) during 3 years led to a decrease in arterial stiffness [12] . A large trial investigating high-dose vitamin K2 (360 μg of MK7) in coronary calcifi cation is ongoing in the Netherlands (VitaK-CAC) [13] .
In a randomized controlled study by Fulton et al. 80 older people were given either 100 mg of vitamin K2 (MK7) or placebo daily over 6 months. The blood pressure did not change [14] . It should be added that the dose used by Fulton et al. was moderate [15] . In a small randomized study comparing vitamin K2 (1.5 mg daily of menaquinone 4 -MK4) and placebo a reduction in both SBP and DBP was observed, but the results remained inconclusive in this respect since a decrease in blood pressure was observed in the control group as well [16] . Menaquinones of various length are naturally produced by the intestinal microbiome and may have different biological functions. This is an area of ongoing research; one of its fruits is the latterly introduced concept of menaquinotype [17] .
In a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) study vitamin K1 (phylloquinone) intake inversely correlated with elevated blood pressure [18] . There are also other strong data indicating that a simultaneous supplementation with vitamins K and D could lower blood pressure [19] . Interestingly, in a group of 1035 patients ucMGP positively associated with the renal resitive index [20] .
A major limitation of this preliminary observational, cross-sectional study is the small sample size, which both reduces the chance of fi nding a true effect and increases the probability of a false positive fi nding [21] . In order to address this problem, we used various approaches to the data, one of which (Spearman's rank-sum correlation) did not replicate the main fi nding. On the one hand, the forward stepwise regression, which is a useful tool for identifying correlations, is known to inflate the signifi cance of fi ndings. On the other hand, the t test, which is robust, indicated a highly signifi cant fi nding and a linear correlation between the raw (non-categorized) PIVKA-II levels and DBP was also confi rmed. As a consequence, the thought-provoking fi nding that we present herein should be interpreted with due caution.
Conclusion
The relationship between vitamin K defi ciency and low DBP in young adults should be investigated further.
